Insider transactions

EDGAR

NOVAVAX, INC

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 88

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-06-20 Filed 2026-06-23DOUGLAS RICHARD Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,880——73,220Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
Open filing 0001104659-26-076927 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23DOUGLAS RICHARD Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (18,880)
Disposed (D)18,8800—0Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F4 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Open filing 0001104659-26-076927 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23Alton Gregg H Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,880——47,685Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
Open filing 0001104659-26-076924 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23Alton Gregg H Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (18,880)
Disposed (D)18,8800—0Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F4 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Open filing 0001104659-26-076924 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23King Rachel K. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,880——44,070Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
Open filing 0001104659-26-076928 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23King Rachel K. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (18,880)
Disposed (D)18,8800—0Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F4 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Open filing 0001104659-26-076928 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23MCGLYNN MARGARET G Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,880——44,468Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
Open filing 0001104659-26-076926 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23MCGLYNN MARGARET G Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (18,880)
Disposed (D)18,8800—0Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F4 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Open filing 0001104659-26-076926 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23Rodgers Richard J Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,880——47,370Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
Open filing 0001104659-26-076930 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23Rodgers Richard J Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (18,880)
Disposed (D)18,8800—0Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F4 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Open filing 0001104659-26-076930 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23MOTT DAVID M Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,880——79,770Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
Open filing 0001104659-26-076925 Read from the filing’s XML Dispute this row
2026-06-20 Filed 2026-06-23MOTT DAVID M Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (18,880)
Disposed (D)18,8800—0Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F4 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076925 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23DOUGLAS RICHARD Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,270) — exercise price 9.13
Acquired (A)21,2700—21,270Direct (D) No
F2
  • F2 One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076927 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23DOUGLAS RICHARD Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,180)
Acquired (A)14,1800—14,180Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076927 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Alton Gregg H Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,270) — exercise price 9.13
Acquired (A)21,2700—21,270Direct (D) No
F2
  • F2 One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076924 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Alton Gregg H Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,180)
Acquired (A)14,1800—14,180Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076924 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23King Rachel K. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,270) — exercise price 9.13
Acquired (A)21,2700—21,270Direct (D) No
F2
  • F2 One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076928 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23King Rachel K. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,180)
Acquired (A)14,1800—14,180Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076928 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23MCGLYNN MARGARET G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,270) — exercise price 9.13
Acquired (A)21,2700—21,270Direct (D) No
F2
  • F2 One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076926 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23MCGLYNN MARGARET G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,180)
Acquired (A)14,1800—14,180Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076926 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Rodgers Richard J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,270) — exercise price 9.13
Acquired (A)21,2700—21,270Direct (D) No
F2
  • F2 One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076930 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Rodgers Richard J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,180)
Acquired (A)14,1800—14,180Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076930 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23MOTT DAVID M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,270) — exercise price 9.13
Acquired (A)21,2700—21,270Direct (D) No
F2
  • F2 One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076925 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23MOTT DAVID M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,180)
Acquired (A)14,1800—14,180Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076925 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Shiver John W. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,270) — exercise price 9.13
Acquired (A)21,2700—21,270Direct (D) No
F1
  • F1 One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076923 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Shiver John W. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,180)
Acquired (A)14,1800—14,180Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076923 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Newton Charles W. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,270) — exercise price 9.13
Acquired (A)21,2700—21,270Direct (D) No
F1
  • F1 One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076922 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Newton Charles W. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,180)
Acquired (A)14,1800—14,180Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Novavax, Inc. (the Company) common stock.
  • F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Open filing 0001104659-26-076922 Read from the filing’s XML Dispute this row
2026-04-25 Filed 2026-04-28Newton Charles W. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)9,5200—9,520Direct (D) No— Open filing 0001104659-26-050457 Read from the filing’s XML Dispute this row
2026-04-25 Filed 2026-04-28Newton Charles W. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (9,520) — exercise price 0
Disposed (D)9,5200.00
0

Derived: shares × price per share. Exact value 0.00.

19,040Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Company common stock.
  • F2 The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of April 25, 2025, in each case subject to continued service on the Company's Board of Directors through such vesting date.
Open filing 0001104659-26-050457 Read from the filing’s XML Dispute this row
2026-04-14 Filed 2026-04-16Walker Robert Edward Officer: EVP, RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (99,500) — exercise price 8.46
Acquired (A)99,5000.00
0

Derived: shares × price per share. Exact value 0.00.

99,500Direct (D) No
F1
  • F1 Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the Company) Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Open filing 0001104659-26-044486 Read from the filing’s XML Dispute this row
2026-04-14 Filed 2026-04-16Walker Robert Edward Officer: EVP, RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (66,000)
Acquired (A)66,0000.00
0

Derived: shares × price per share. Exact value 0.00.

6,600Direct (D) No
F2, F3
  • F2 Each RSU represents a contingent right to receive one share of the Company common stock.
  • F3 The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.
Open filing 0001104659-26-044486 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-12Shiver John W. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)7,9470—7,947Direct (D) No— Open filing 0001104659-26-027143 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-12Shiver John W. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (7,947) — exercise price 0
Disposed (D)7,9470.00
0

Derived: shares × price per share. Exact value 0.00.

15,893Direct (D) No
F1
  • F1 The RSUs subject to this grant under the Restated 2015 Stock Incentive Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of March 10, 2025, in each case subject to continued service on the Company's Board of Directors through such vesting date
Open filing 0001104659-26-027143 Read from the filing’s XML Dispute this row
2026-03-07 Filed 2026-03-09Kelly James Patrick Officer: EVP, CFO and Treasurer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)12,2230—136,503Direct (D) No— Open filing 0001104659-26-025369 Read from the filing’s XML Dispute this row
2026-03-07 Filed 2026-03-09Kelly James Patrick Officer: EVP, CFO and Treasurer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5,9049.98
58,921.92

Derived: shares × price per share. Exact value 58921.92.

130,599Direct (D) No
F1
  • F1 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
Open filing 0001104659-26-025369 Read from the filing’s XML Dispute this row
2026-03-07 Filed 2026-03-09Kelly James Patrick Officer: EVP, CFO and Treasurer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (12,223) — exercise price 0
Disposed (D)12,2230—0Direct (D) No
F2
  • F2 One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date.
Open filing 0001104659-26-025369 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Draghia-Akli Ruxandra Officer: EVP, Research Development
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)26,6670.00
0

Derived: shares × price per share. Exact value 0.00.

34,876Direct (D) No— Open filing 0001104659-26-023709 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Draghia-Akli Ruxandra Officer: EVP, Research Development
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)11,3139.49
107,360.37

Derived: shares × price per share. Exact value 107360.37.

23,563Direct (D) No
F1
  • F1 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
Open filing 0001104659-26-023709 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Draghia-Akli Ruxandra Officer: EVP, Research Development
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Units — underlying Common Stock (26,667) — exercise price 0
Disposed (D)26,6670—53,333Direct (D) No
F4
  • F4 One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date.
Open filing 0001104659-26-023709 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Casey Mark J Officer: EVP, Chief Legal Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)37,5000—101,445Direct (D) No— Open filing 0001104659-26-023715 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Casey Mark J Officer: EVP, Chief Legal Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)11,3789.49
107,977.22

Derived: shares × price per share. Exact value 107977.22.

90,067Direct (D) No
F1
  • F1 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
Open filing 0001104659-26-023715 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Casey Mark J Officer: EVP, Chief Legal Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (4,000) — exercise price 0
Disposed (D)4,0000—4,000Direct (D) No
F2
  • F2 One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the Plan) vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date.
Open filing 0001104659-26-023715 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Jacobs John C Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)150,1670—264,130Direct (D) No— Open filing 0001104659-26-023726 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Jacobs John C Director · Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)69,2889.49
657,543.12

Derived: shares × price per share. Exact value 657543.12.

225,680Direct (D) No
F1
  • F1 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
Open filing 0001104659-26-023726 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Jacobs John C Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (150,167) — exercise price 0
Disposed (D)150,1670—300,333Direct (D) No
F2
  • F2 One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the Plan) vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date.
Open filing 0001104659-26-023726 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kelly James Patrick Officer: EVP, CFO and Treasurer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)43,1670—145,130Direct (D) No— Open filing 0001104659-26-023731 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kelly James Patrick Officer: EVP, CFO and Treasurer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)20,8509.49
197,866.5

Derived: shares × price per share. Exact value 197866.50.

124,280Direct (D) No
F1
  • F1 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
Open filing 0001104659-26-023731 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kelly James Patrick Officer: EVP, CFO and Treasurer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (43,167) — exercise price 0
Disposed (D)43,1670—86,333Direct (D) No
F2
  • F2 One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on each of the first three (3) anniversaries of March 1, 2024, in each case subject to continued employment through such vesting date.
Open filing 0001104659-26-023731 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05O'Hara Elaine Officer: EVP, Chief Strategy Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)56,3340—157,071Direct (D) No— Open filing 0001104659-26-023720 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 305

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Sculptor Capital LP Partly reported under another manager20,342,000 PRN25,087,687 dollarsHigher by 90,000 Prior quarter: 20,252,000Open filing 0001193125-26-460943 Filed 2026-11-13 Dispute this row
BlackRock, Inc. Partly reported under another manager15,594,410 SH168,575,572 dollarsHigher by 1,647,529 Prior quarter: 13,946,881Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
SHAH CAPITAL MANAGEMENT 12,173,481 SH131,595,330 dollarsLower by 1,992,096 Prior quarter: 14,165,577Open filing 0001398344-26-018061 Filed 2026-10-09 Dispute this row
STATE STREET CORP Partly reported under another manager8,827,707 SH95,427,513 dollarsLower by 2,912,843 Prior quarter: 11,740,550Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 7,249,353 SH78,365,506 dollarsLower by 358,643 Prior quarter: 7,607,996Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 7,232,300 SH78,181,163 dollarsLower by 25,149 Prior quarter: 7,257,449Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Sanofi 6,880,481 SH74,378,000 dollarsUnchanged Prior quarter: 6,880,481Open filing 0001193125-26-448717 Filed 2026-11-05 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager5,732,460 SH61,967,893 dollarsHigher by 81,555 Prior quarter: 5,650,905Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 5,512,174 SH59,586,601 dollarsHigher by 1,421,131 Prior quarter: 4,091,043Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 4,400,000 PRN5,333,240 dollarsUnchanged Prior quarter: 4,400,000Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager4,230,566 SH45,742,207 dollarsHigher by 23,196 Prior quarter: 4,207,370Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
COATUE MANAGEMENT LLC Partly reported under another manager3,836,986 SH41,477,819 dollarsUnchanged Prior quarter: 3,836,986Open filing 0000919574-26-007862 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager3,792,332 SH40,995,109 dollarsHigher by 376,097 Prior quarter: 3,416,235Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager2,983,320 SH32,249,690 dollarsLower by 24,436 Prior quarter: 3,007,756Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager2,783,375 SH30,088,284 dollarsHigher by 1,088,062 Prior quarter: 1,695,313Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
HRT FINANCIAL LP 2,576,691 SH27,854 dollarsNot in the prior quarter’s filings read Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
JUPITER ASSET MANAGEMENT LTD 2,467,223 SH26,670,681 dollarsHigher by 1,396,991 Prior quarter: 1,070,232Open filing 0001171843-26-007304 Filed 2026-11-10 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager2,431,500 SH26,284,515 dollarsHigher by 459,900 Prior quarter: 1,971,600Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Graham Capital Management, L.P. Option: Put 2,087,700 SH22,568,037 dollarsHigher by 1,100 Prior quarter: 2,086,600Open filing 0002048251-26-009806 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager1,603,000 PRN1,960,431 dollarsLower by 90,000 Prior quarter: 1,693,000Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Invesco Ltd. Partly reported under another manager1,483,912 SH16,041,088 dollarsHigher by 1,247,908 Prior quarter: 236,004Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,439,482 SH15,560,800 dollarsHigher by 92,875 Prior quarter: 1,346,607Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
TSP Capital Management Group, LLC 1,432,365 SH15,483,868 dollarsHigher by 13,000 Prior quarter: 1,419,365Open filing 0001172661-26-004556 Filed 2026-10-15 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager1,430,179 SH15,460,236 dollarsLower by 17,929 Prior quarter: 1,448,108Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Caption Management, LLC Option: Put 1,393,300 SH15,061,573 dollarsHigher by 1,293,300 Prior quarter: 100,000Open filing 0001706766-26-000008 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager1,356,158 SH14,660,068 dollarsLower by 513,501 Prior quarter: 1,869,659Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Trexquant Investment LP Partly reported under another manager1,333,952 SH14,420,021 dollarsHigher by 872,210 Prior quarter: 461,742Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row
Allianz Asset Management GmbH Partly reported under another manager1,176,013 SH12,712,701 dollarsLower by 403,187 Prior quarter: 1,579,200Open filing 0001193125-26-463640 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 1,076,833 SH11,640,565 dollarsLower by 8,267 Prior quarter: 1,085,100Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager1,063,875 SH11,500,489 dollarsHigher by 360,869 Prior quarter: 703,006Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
MILLENNIUM MANAGEMENT LLC 1,061,711 SH11,477,096 dollarsLower by 706,452 Prior quarter: 1,768,163Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Put Partly reported under another manager991,300 SH10,715,953 dollarsHigher by 77,900 Prior quarter: 913,400Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
GROUP ONE TRADING LLC Option: Put 922,600 SH9,973,306 dollarsHigher by 160,100 Prior quarter: 762,500Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
Jump Financial, LLC Partly reported under another manager905,872 SH9,792,476 dollarsHigher by 701,057 Prior quarter: 204,815Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
FMR LLC Partly reported under another manager867,253 SH9,375,002 dollarsHigher by 258,349 Prior quarter: 608,904Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager854,419 SH9,236,266 dollarsHigher by 4,701 Prior quarter: 849,718Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
CITADEL ADVISORS LLC Option: Put Partly reported under another manager844,700 SH9,131,207 dollarsLower by 791,100 Prior quarter: 1,635,800Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
BARCLAYS PLC Partly reported under another manager771,881 SH8,344,034 dollarsHigher by 630,914 Prior quarter: 140,967Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
MORGAN STANLEY Partly reported under another manager619,843 SH6,700,520 dollarsHigher by 153,387 Prior quarter: 466,456Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
UBS Group AG Option: Call Partly reported under another manager617,263 SH6,672,613 dollarsHigher by 245,751 Prior quarter: 371,512Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
IMC-Chicago, LLC Option: Call 569,400 SH6,155,214 dollarsHigher by 62,600 Prior quarter: 506,800Open filing 0001452861-26-000007 Filed 2026-11-05 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager510,210 SH5,433,737 dollarsHigher by 499,530 Prior quarter: 10,680Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
CITADEL ADVISORS LLC Option: Call Partly reported under another manager501,900 SH5,425,539 dollarsHigher by 22,200 Prior quarter: 479,700Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager462,141 SH4,995,744 dollarsLower by 190,632 Prior quarter: 652,773Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager410,992 SH4,442,824 dollarsLower by 95,091 Prior quarter: 506,083Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Option: Call Partly reported under another manager409,100 SH4,422,371 dollarsHigher by 122,400 Prior quarter: 286,700Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Marshall Financial Group, LLC 404,016 SH4,367,413 dollarsNot in the prior quarter’s filings read Open filing 0002085853-26-001375 Filed 2026-11-12 Dispute this row
CITIGROUP INC Option: Call Partly reported under another manager385,700 SH4,169,417 dollarsLower by 86,000 Prior quarter: 471,700Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
GROUP ONE TRADING LLC Option: Call 360,100 SH3,892,681 dollarsLower by 21,300 Prior quarter: 381,400Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
TUDOR INVESTMENT CORP ET AL Option: Call 347,100 SH3,752,151 dollarsLower by 89,800 Prior quarter: 436,900Open filing 0000902664-26-004567 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Sixth Street Partners Management Company, L.P. 1,346,607 SH
  • Point72 Asset Management, L.P. 664,286 SH
  • Monaco Asset Management SAM 577,464 SH
  • Edgestream Partners, L.P. 559,796 SH
  • DIMENSIONAL FUND ADVISORS LP 396,711 SH
  • FIRST TRUST ADVISORS LP 385,699 SH
  • Aquatic Capital Management LLC 153,665 SH
  • NOMURA HOLDINGS INC 150,000 SH
  • Squarepoint Ops LLC 133,562 SH
  • IEQ CAPITAL, LLC 101,355 SH
  • NewEdge Wealth, LLC 100,559 SH
  • NOMURA HOLDINGS INC 100,000 SH
  • Balyasny Asset Management L.P. 82,240 SH
  • SG Americas Securities, LLC 66,837 SH
  • Mariner, LLC 63,368 SH
  • Jupiter Topco LLC 60,815 SH
  • WELLINGTON MANAGEMENT GROUP LLP 57,136 SH
  • NOMURA HOLDINGS INC 55,683 SH
  • ALPS ADVISORS INC 48,989 SH
  • INTECH INVESTMENT MANAGEMENT LLC 43,278 SH
  • Atom Investors LP 38,175 SH
  • CITIGROUP INC 35,000 SH
  • VARCOV Co. 29,403 SH
  • Kestra Advisory Services, LLC 28,636 SH
  • Freestone Grove Partners LP 26,223 SH
  • DRW Securities, LLC 25,697 SH
  • MILLENNIUM MANAGEMENT LLC 22,500 SH
  • CAPTRUST FINANCIAL ADVISORS 18,675 SH
  • Corient Private Wealth LP 16,412 SH
  • OXFORD ASSET MANAGEMENT LLP 15,921 SH
  • Bridgefront Capital, LLC 13,410 SH
  • BRIGHTON JONES LLC 11,427 SH
  • TWO SIGMA SECURITIES, LLC 10,323 SH
  • Integrated Wealth Concepts LLC 4,415 SH
  • Pacer Advisors, Inc. 3,486 SH
  • Essential Partners LLC 856 SH
  • Aberdeen Wealth Management LLC 660 SH
  • Bulwark Capital Corp 610 SH
  • ROYAL BANK OF CANADA 200 SH
  • True Wealth Design, LLC 196 SH
  • Spectrum Wealth Advisory Group, LLC 150 SH
  • Wealth Enhancement Trust Services, Inc. 117 SH
  • REYL Cie S.A. 100 SH
  • INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC 100 SH
  • Clearstead Advisors, LLC 97 SH
  • Stone House Investment Management, LLC 44 SH
  • Darwin Wealth Management, LLC 25 SH
  • THURSTON, SPRINGER, MILLER, HERD TITAK, INC. 20 SH
  • FIDUCIARY FINANCIAL ADVISORS 20 SH
  • JPL Wealth Management, LLC 12 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Shah Capital Management Common Stock, Par Value $0.01 per share6.3910,543,476.0010/16/2026 Filed 2026-10-16SCHEDULE 13D/AAmendment 8Open filing 0001398344-26-018323 Dispute this row
Shah Capital Fund LLC Common Stock, Par Value $0.01 per share3.786,230,000.0010/16/2026 Filed 2026-10-16SCHEDULE 13D/AAmendment 8Open filing 0001398344-26-018323 Dispute this row
Himanshu H. Shah Common Stock, Par Value $0.01 per share6.4610,656,964.0010/16/2026 Filed 2026-10-16SCHEDULE 13D/AAmendment 8Open filing 0001398344-26-018323 Dispute this row
Shah Capital Management Common Stock, Par Value $0.01 per share6.3910,543,476.0010/16/2026 Filed 2026-10-16SCHEDULE 13GOpen filing 0001398344-26-018328 Dispute this row
Shah Capital Fund LLC Common Stock, Par Value $0.01 per share3.786,230,000.0010/16/2026 Filed 2026-10-16SCHEDULE 13GOpen filing 0001398344-26-018328 Dispute this row
Himanshu H. Shah Common Stock, Par Value $0.01 per share6.4610,656,964.0010/16/2026 Filed 2026-10-16SCHEDULE 13GOpen filing 0001398344-26-018328 Dispute this row
STATE STREET CORPORATION COMMON STOCK5.48,827,707.0009/30/2026 Filed 2026-11-10SCHEDULE 13GOpen filing 0000093751-26-000697 Dispute this row
STATE STREET CORPORATION COMMON STOCK7.111,740,566.0006/30/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0000093751-26-000510 Dispute this row
Shah Capital Management Common Stock, Par Value $0.01 per share8.9514,714,705.0005/14/2026 Filed 2026-05-15SCHEDULE 13D/AAmendment 7Open filing 0001398344-26-009210 Dispute this row
Shah Capital Opportunity Fund LP Common Stock, Par Value $0.01 per share8.5114,000,000.0005/14/2026 Filed 2026-05-15SCHEDULE 13D/AAmendment 7Open filing 0001398344-26-009210 Dispute this row
Himanshu H. Shah Common Stock, Par Value $0.01 per share9.0314,841,000.0005/14/2026 Filed 2026-05-15SCHEDULE 13D/AAmendment 7Open filing 0001398344-26-009210 Dispute this row
Shah Capital Management Common Stock, Par Value $0.01 per share9.0314,719,738.0004/08/2026 Filed 2026-04-08SCHEDULE 13D/AAmendment 6Open filing 0001398344-26-006235 Dispute this row
Shah Capital Opportunity Fund LP Common Stock, Par Value $0.01 per share8.5914,000,000.0004/08/2026 Filed 2026-04-08SCHEDULE 13D/AAmendment 6Open filing 0001398344-26-006235 Dispute this row
Himanshu H. Shah Common Stock, Par Value $0.01 per share9.1114,845,097.0004/08/2026 Filed 2026-04-08SCHEDULE 13D/AAmendment 6Open filing 0001398344-26-006235 Dispute this row
Vanguard Capital Management Common Stock5.098,305,68103/31/2026 Filed 2026-04-30SCHEDULE 13GOpen filing 0002100119-26-000933 Dispute this row
BANK OF AMERICA CORP /DE/ Common Stock4.16,655,398.0003/31/2026 Filed 2026-04-27SCHEDULE 13G/AAmendment 1Open filing 0000070858-26-000241 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-27SCHEDULE 13G/AAmendment 7Open filing 0000102909-26-001957 Dispute this row
BANK OF AMERICA CORP /DE/ Common Stock5.18,315,530.0012/31/2025 Filed 2026-02-11SCHEDULE 13GOpen filing 0000070858-26-000073 Dispute this row
STATE STREET CORPORATION COMMON STOCK5.99,523,646.0012/31/2025 Filed 2026-02-09SCHEDULE 13GOpen filing 0000093751-26-000075 Dispute this row
Shah Capital Management Common Stock, Par Value $0.01 per share8.213,392,523.0011/10/2025 Filed 2025-11-12SCHEDULE 13D/AAmendment 5Open filing 0001398344-25-020786 Dispute this row
Shah Capital Opportunity Fund LP Common Stock, Par Value $0.01 per share7.812,650,000.0011/10/2025 Filed 2025-11-12SCHEDULE 13D/AAmendment 5Open filing 0001398344-25-020786 Dispute this row
Himanshu H. Shah Common Stock, Par Value $0.01 per share8.313,461,780.0011/10/2025 Filed 2025-11-12SCHEDULE 13D/AAmendment 5Open filing 0001398344-25-020786 Dispute this row
Shah Capital Management Common Stock, Par Value $0.01 per share7.211,742,523.0010/13/2025 Filed 2025-10-14SCHEDULE 13D/AAmendment 4Open filing 0001398344-25-019099 Dispute this row
Shah Capital Opportunity Fund LP Common Stock, Par Value $0.01 per share6.811,000,000.0010/13/2025 Filed 2025-10-14SCHEDULE 13D/AAmendment 4Open filing 0001398344-25-019099 Dispute this row
Himanshu H. Shah Common Stock, Par Value $0.01 per share7.311,811,780.0010/13/2025 Filed 2025-10-14SCHEDULE 13D/AAmendment 4Open filing 0001398344-25-019099 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,735,210 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015151,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to NOVAVAX, INC